68Ga-PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate cancer Perspective of radiologist

被引:8
|
作者
Wang, Liwei [1 ]
Yu, Fei [2 ]
Yang, Lulu [3 ]
Zang, Shiming [2 ]
Xue, Hailin [1 ]
Yin, Xindao [1 ]
Guo, Hongqian [4 ]
Sun, Hongbin [5 ]
Wang, Feng [2 ]
机构
[1] Nanjing Med Univ, Nanjing Hosp 1, Dept Radiol, Nanjing, Peoples R China
[2] Nanjing Med Univ, Nanjing Hosp 1, Dept Nucl Med, 68th Changle Rd, Nanjing 210006, Peoples R China
[3] Nanjing Med Univ, Nanjing Hosp 1, Dept Pathol, Nanjing, Peoples R China
[4] Nanjing Univ, Med Sch, Dept Urol, Drum Tower Hosp, Nanjing, Peoples R China
[5] Nanjing Med Univ, Nanjing Hosp 1, Dept Urol, 68th Changle Rd, Nanjing 210006, Peoples R China
基金
中国国家自然科学基金;
关键词
magnetic resonance imaging (MRI); positron emission computed tomography (PET); prostate cancer; prostate-specific membrane antigen (PSMA); MULTI-PARAMETRIC MRI; MULTIPARAMETRIC MRI; GLEASON SCORE; PET/MRI; BIOPSY; ACCURACY; LESIONS;
D O I
10.1097/MD.0000000000020755
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ga-68-PSMA-11 positron emission computed tomography /computed tomography (PET/CT) is more sensitive than magnetic resonance imaging (MRI) in detecting prostate cancer (PCa). We evaluated the value of(68)Ga-PSMA-11 PET/CT with MRI in treatment-naive PCa. This retrospective study was approved by the hospital ethics committee. The MRI and(68)Ga-PSMA-11 PET/CT imaging data of 63 cases of highly suspected PCa were enrolled in this study. The SUV(max)and apparent diffusion coefficient (ADC), and their ratio, were assessed as diagnostic markers to distinguish PCa from benign disease. There were 107 prostate lesions detected in 63 cases. Forty cases with 64 malignant primary lesions were confirmed PCa, whereas 23 cases had 43 benign lesions. PSMA-avid lesions correlated with hypointense signal on ADC maps and hyperintense signal on diffusion-weighted imaging. The ADC of PCa was lower than that of benign lesions, and SUV(max)and SUVmax/ADC of PCa was higher than that of benign lesions (P < .01). ADC had significant negative correlation with Gleason score (GS) and SUVmax, SUVmax, and SUVmax/ADC positively correlated with GS. From ROC analysis, we established cutoff values of ADC, SUVmax, and SUVmax/ADC at 1.02 x 10(-3)mm(2)/s, 11.72, and 12.35, respectively, to differentiate PCa from benign lesions. The sensitivity, specificity, and AUC were 90.6%, 58.1%, and 0.816 for ADC, 67.2%, 97.7%, and 0.905 for SUVmax, and 81.2%, 88.4%, and 0.929 for SUVmax/ADC, respectively. Ga-68-PSMA-11 PET/CT combined with MRI offers higher diagnostic efficacy in the detection of PCa than either modality alone.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients
    Zang, Shiming
    Shao, Guoqiang
    Cui, Can
    Li, Tian-Nv
    Huang, Yue
    Yao, Xiaochen
    Fan, Qiu
    Chen, Zejun
    Du, Jin
    Jia, Ruipeng
    Sun, Hongbin
    Hua, Zichun
    Tang, Jun
    Wang, Feng
    ONCOTARGET, 2017, 8 (07) : 12247 - 12258
  • [32] 68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?
    Christian Uprimny
    Wiener Medizinische Wochenschrift, 2019, 169 : 3 - 11
  • [33] Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
    Calais, Jeremie
    Fendler, Wolfgang P.
    Eiber, Matthias
    Gartmann, Jeannine
    Chu, Fang-I
    Nickols, Nicholas G.
    Reiter, Robert E.
    Rettig, Matthew B.
    Marks, Leonard S.
    Ahlering, Thomas E.
    Huynh, Linda M.
    Slavik, Roger
    Gupta, Pawan
    Quon, Andrew
    Allen-Auerbach, Martin S.
    Czernin, Johannes
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) : 434 - 441
  • [34] Staging Prostate Cancer with 68Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?
    Kesler, Mikhail
    Cohen, Dan
    Levine, Charles
    Sarid, David
    Keizman, Daniel
    Yossepowitch, Ofer
    Even-Sapir, Einat
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (07) : 1030 - 1035
  • [35] 68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?
    Uprimny, Christian
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2019, 169 (1-2) : 3 - 11
  • [36] PET/CT with 68Ga-PSMA-11 for detection of rib involvement in a subgroup of prostate cancer patients
    Calderoni, L.
    Farolfi, A.
    Mei, R.
    Telo, S.
    Fanti, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S592 - S592
  • [37] Diagnostic Performance of 68Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer
    Light, Alexander
    Lazic, Stefan
    Houghton, Kate
    Bayne, Max
    Connor, Martin J.
    Tam, Henry
    Ahmed, Hashim U.
    Shah, Taimur T.
    Barwick, Tara D.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (03) : 379 - 385
  • [38] Comparison of 68Ga-PSMA-11 PET/CT and 18F-Fluciclovine PET/CT in recurrent Prostate Cancer
    Ceci, F.
    Polverari, G.
    Gartmann, J.
    Fendler, W.
    Eiber, M.
    Herrmann, K.
    Czernin, J.
    Calais, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S150 - S150
  • [39] Localizing biochemical recurrence of prostate cancer using 68Ga-PSMA-11 PET/CT and 11C-acetate PET/CT
    Regula, N.
    Kostaras, V.
    Johansson, S.
    Pulido, C.
    Lindstrom, E.
    Lubberink, M.
    Velikyan, I.
    Sorensen, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S27 - S27
  • [40] Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients
    Leon Will
    Frederik L. Giesel
    Martin T. Freitag
    Anne K. Berger
    Walter Mier
    Klaus Kopka
    Stefan A. Koerber
    Hendrik Rathke
    Christophe Kremer
    Clemens Kratochwil
    Hans-Ulrich Kauczor
    Uwe Haberkorn
    Tim F. Weber
    Cancer Imaging, 17